APA (7th ed.) Citation

SJJPM, M., RPMG, H., GICG, E., NMA, B., & TM, G. (2025). The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 28(2), 224. https://doi.org/10.1016/j.jval.2024.12.005

Chicago Style (17th ed.) Citation

SJJPM, Metsemakers, Hermens RPMG, Ector GICG, Blijlevens NMA, and Govers TM. "The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction." Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 28, no. 2 (2025): 224. https://doi.org/10.1016/j.jval.2024.12.005.

MLA (9th ed.) Citation

SJJPM, Metsemakers, et al. "The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction." Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 28, no. 2, 2025, p. 224, https://doi.org/10.1016/j.jval.2024.12.005.